When: Confirmed close above $64.50 with rising volume AND MACD histogram turning positive (flips 50 SMA higher)

Then: Add second tranche of equal size to first

When: Pullback to $58-60 near 200 SMA ($58.17) with confirmed bullish daily divergence AND no further CYTK escalation

Then: Add second tranche of equal size to first as mean-reversion entry

When: Closing basis below $58.00 (200 SMA breakdown)

Then: Full exit — invalidates long-term uptrend and confirms bear's value-trap thesis

When: Price at $61.50 (lower Bollinger Band)

Then: Re-evaluate position sizing

Wait for confirmation (close above $64.50 with rising volume) or better entry ($58-60 zone), or alternatively enter with 0.5% position size and wider stop at $56.50 with no second tranche unless breakout confirmed.

• Q2 2026 net income of $3.32B on $12.97B revenue represents 25.6% net margin normalization, not fundamental improvement, as Q2 2025 was depressed to 10.7% net margin from acquisition charges
• Normalized earnings of $6.05 per share versus street estimate of $6.56 implies 8% additional growth priced in on an already aggressive basis
• PEG ratio of 17.56 reflects aggressive growth assumptions in a defensive name; if Q3 prints 5% below consensus, re-rates to 10.5x forward multiple yielding $63 stock
• Eliquis at ~30% of revenue faces 70-90% generic erosion within 18 months upon loss of exclusivity (2026-2027); $7-10B erosion cannot be absorbed by Sotyktu, Cobenfy, or Reblozyl
• Technical setup is bearish: 50 SMA at $64.11 rolled over and sloping downward, price $1.06 above lower Bollinger Band at $61.56, MACD crossed bearish September 15 with histogram at -0.52, RSI at 38.77
• The September 18 volume spike of 36.8 million shares could represent forced-selling capitulation and short-covering, not institutional accumulation
• Current stop at $57.90 is essentially at the 200 SMA at $58.17; if breached, downside extends to $54-56 zone indicating failed long-term trend
• Position sizing of 0.75% on $100M portfolio equals $750,000; stop hit generates $73,500 realized loss plus slippage and tax friction

→ vs aggressive: The 44% one-year return and 153% Q2 net income growth reflect base normalization from depressed Q2 2025 ($1.31B net income, 10.7% margin), not fundamental improvement; the market has already captured this normalization in the $52-$68 move

→ vs aggressive: The PEG ratio of 17.56 is not merely a 'transitional artifact' but evidence the market has stretched to a best-case scenario; even using normalized EPS of $6.05, the street is still pricing in 8% growth above the most recent quarter

→ vs aggressive: The patent cliff representing ~30% of revenue with 70-90% generic erosion cannot be dismissed as 'already priced in' without knowing the exact timing, authorized generic launch, or litigation outcomes; the math does not work given Sotyktu, Cobenfy, and Reblozyl constraints

→ vs aggressive: The September 18 volume spike is ambiguous—could be capitulation and short-covering rather than institutional accumulation; building a buy thesis on a single ambiguous volume bar is 'storytelling, not analysis'

→ vs aggressive: The 'act now or miss it' framing creates pressure to buy tops; the stock has been around for decades and there will be other entries if this one doesn't work

→ vs aggressive: The proposed stop at $57.90 essentially at the 200 SMA ($58.17) fails to preserve capital because a breach means the long-term trend has failed and the stop gets hit during a breakdown to $54-56

BUY with reduced initial tranche (0.6%-0.75%) and disciplined entry at $61.50-$62.50, stop at $58.00

• Forward P/E of 9.5x and 4% covered dividend support bull case
• Q2 2026 earnings beat with $12.4B annualized revenue and 25.6% net margin
• Trailing FCF of $8.1B demonstrates successful restructuring
• Recommends initial tranche of 0.6%-0.75% (vs aggressive 1%-2%)
• Disciplined entry preferred near $61.50-$62.50 with tag of lower Bollinger Band at $61.56
• Stop at $58.00 aligned with 200 SMA at $58.17
• Second tranche unchanged at $64.50 breakout or $58-$60 pullback
• Neither colleague addressed correlated pharma exposure in portfolios
• No-cut environment (96% probability) provides floor but caps upside through multiple expansion
• September 18 volume spike of 36.8M shares is ambiguous (could be forced selling, index rebalancing, or short-covering)

→ vs aggressive: Urgency is partially manufactured; short-duration Treasuries yielding 4%+ mean opportunity cost of waiting is not zero

→ vs aggressive: Risks (patent cliff, IRA) are not definitively priced in; claiming everything is priced is rationalization, not analysis

→ vs aggressive: September 18 volume spike interpretation as institutional accumulation is one possible reading, not confirmed fact

→ vs conservative: Bear case treated as base case; $63 worst-case if 5% Q3 miss is essentially flat case with extra steps, not true bear case

→ vs conservative: Stop at $57.90 is doing its job correctly; moving to $56.50 increases risk to 9.6% vs 7.5% proposed

→ vs conservative: Realistic bear case is $60 or $58, not $63; $57.90 stop already targets 200 SMA where mean-reversion bounce is likely